Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable outcomes in
individuals with hematological malignancies, but its success has been hindered by barriers …

Over the past several decades, mRNA vaccines have evolved from a theoretical concept to a
clinical reality. These vaccines offer several advantages over traditional vaccine techniques …

Although chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B
cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development …

Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but
existing systems have shortcomings including leakiness and attenuated activity. Here, we …

Synthetic gene circuits that precisely control human cell function could expand the
capabilities of gene-and cell-based therapies. However, platforms for developing circuits in …

Patient-derived T cells genetically reprogrammed to express CD19-specific chimeric antigen
receptors (CARs) have shown remarkable clinical responses and are commercially …

Ovarian cancer is the most lethal gynecologic malignancy. Surgery and chemotherapy are
the primary treatments for ovarian cancer; however, patients often succumb to recurrence …

Chimeric antigen receptor (CAR)-T cells showed great activity in hematologic malignancies.
However, heterogeneous antigen expression in tumor cells and suboptimal CAR-T-cell …

Hepatocellular carcinoma (HCC) is the most prevalent primary liver cancer with poor
prognosis. Surgery, chemotherapy, and radiofrequency ablation are three conventional …

Rapid advances in synthetic biology are driving the development of genetically engineered
microbes as therapeutic agents for a multitude of human diseases, including cancer. The …